We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...
Read moreWe discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreWe explore the pricing dynamics of biosimilars, which depend on the type of biosimilar, its indicati...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreOn 28th September there was a two-hour public hearing on the GKV Financial Stabilisation Act. There ...
Read moreThe legislation is an updated, smaller version of The Build Back Better Act (BBBA) which the US Sena...
Read moreLegislation published in the Journal Officiel on 14th April 2022 establishes a first list of similar...
Read morePatents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...
Read moreBiosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...
Read more